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Dissolution dynamic nuclear polarisation (dDNP) of 13C-labelled pyruvate in magnetic
resonance spectroscopy/imaging (MRS/MRSI) has the potential for monitoring
tumour progression and treatment response. Pyruvate delivery, its metabolism to lac-
tate and efflux were investigated in rat P22 sarcomas following simultaneous intrave-
nous administration of hyperpolarised 13C-labelled pyruvate (13C1-pyruvate) and urea
(13C-urea), a nonmetabolised marker. A general mathematical model of pyruvate-
lactate exchange, incorporating an arterial input function (AIF), enabled the losses of
pyruvate and lactate from tumour to be estimated, in addition to the clearance rate
of pyruvate signal from blood into tumour, Kip, and the forward and reverse fractional
rate constants for pyruvate-lactate signal exchange, kpl and klp. An analogous model
Abbreviations used: AIF, arterial input function (signal per ml arterial blood reaching the tumour as a function of time); AIFmeas, measured signal time-course in the arterial blood chamber; BIR,
B1-insensitive rotation; CL, lactate AIF (arterial lactate signal as a function of time; arbitrary units per ml blood); CP, pyruvate AIF (arterial pyruvate signal as a function of time; arbitrary units per
ml blood); CU, urea AIF (arterial urea signal as a function of time; arbitrary units per ml blood); dDNP, dissolution dynamic nuclear polarisation; E, fraction of solute extracted or cleared from blood
to tissue on a single pass; F, blood flow rate (ml blood per min per ml or g tumour tissue; ml.min1.ml1 or ml.min1.g1); kavail, fractional rate constant for transfer of pyruvate signal from the
nonexchanging to exchanging tumour compartment (fraction of compartment signal transferred per s; s1); Kil, clearance rate of lactate signal from arterial blood into tumour tissue (ml blood
cleared per min per ml tumour tissue; ml.min1.ml1); Kip, clearance rate of pyruvate signal from arterial blood into tumour tissue (ml blood cleared per min per ml tumour tissue; ml.min
1.ml1;
Kiu, clearance rate of urea signal from arterial blood into tumour tissue (ml blood cleared per min per ml tumour tissue; ml.min
1.ml1); klo, fractional loss rate constant for lactate signal due to
efflux from tumour into blood (fraction of compartment signal lost per s; s1); kloss(lactate), fractional rate constant for total loss of lactate signal from tumour (fraction of compartment signal lost
per s; s1); kloss(pyruvate), fractional rate constant for total loss of pyruvate signal from tumour (fraction of compartment signal lost per s; s
1; kloss(urea), fractional rate constant for total loss of urea
signal from tumour (fraction of compartment signal lost per s; s1); klp, reverse fractional rate constant for pyruvate-lactate signal exchange (fraction of compartment signal exchanged per s; s
1);
kpl, forward fractional rate constant for pyruvate-lactate signal exchange (fraction of compartment signal exchanged per s; s
1); kpo, fractional loss rate constant for pyruvate signal due to efflux
from tumour into blood (fraction of compartment signal lost per s; s1); kuo, fractional loss rate constant for urea signal due to efflux from tumour into blood (fraction of compartment signal lost
per s; s1); LP(t), total lactate tumour signal as a function of time, derived from pyruvate delivery (arbitrary units per ml tumour); M(t,n), magnetization as a function of time (n.TR) and excitation
pulse for the nth pulse/data acquisition; Mo, initial magnetization; PA,
13C1-pyruvic acid; PE(t), pyruvate tumour signal in the exchangeable compartment as a function of time (arbitrary units per
ml tumour); PP(t), total pyruvate tumour signal as a function of time, derived from pyruvate delivery (arbitrary units per ml tumour); Rl, lumped fractional rate constant for tumour lactate signal
loss excluding klp (fraction of compartment signal lost per s; s
1); Rp, lumped fractional rate constant for tumour pyruvate signal loss excluding kpl (fraction of compartment signal lost per s; s
1);
Ru, lumped fractional rate constant for tumour urea loss (equivalent to kloss(urea)) (fraction of compartment signal lost per s; s
1); T1l, longitudinal relaxation time for lactate (s); T1p, longitudinal
relaxation time for pyruvate (s); T1u, longitudinal relaxation time for urea (s); UU(t), total urea tumour signal as a function of time (arbitrary units); θ, flip angle.
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was developed for urea, enabling estimation of urea tumour losses and the blood
clearance parameter, Kiu. A spectral fitting procedure to blood time-course data
proved superior to assuming a gamma-variate form for the AIFs. Mean arterial blood
pressure marginally correlated with clearance rates. Kiu equalled Kip, indicating equiv-
alent permeability of the tumour vasculature to urea and pyruvate. Fractional loss
rate constants due to effluxes of pyruvate, lactate and urea from tumour tissue into
blood (kpo, klo and kuo, respectively) indicated that T1s and the average flip angle, θ,
obtained from arterial blood were poor surrogates for these parameters in tumour tis-
sue. A precursor-product model, using the tumour pyruvate signal time-course as the
input for the corresponding lactate signal time-course, was modified to account for
the observed delay between them. The corresponding fractional rate constant, kavail,
most likely reflected heterogeneous tumour microcirculation. Loss parameters, esti-
mated from this model with different TRs, provided a lower limit on the estimates of
tumour T1 for lactate and urea. The results do not support use of hyperpolarised urea
for providing information on the tumour microcirculation over and above what can
be obtained from pyruvate alone. The results also highlight the need for rigorous pro-
cesses controlling signal quantitation, if absolute estimations of biological parameters
are required.
K E YWORD S
dynamic nuclear polarisation, mathematical modelling, P22 rat sarcoma, precursor-product,
pyruvate metabolism, rate constant, tumour microcirculation, urea
1 | INTRODUCTION
Dissolution dynamic nuclear polarisation (dDNP) can vastly increase the magnetic resonance spectroscopy (MRS) sensitivity for 13C nuclei,
allowing real-time measurement of metabolic kinetics, without the interfering background signals experienced in 1H MRS.1,2 13C1-labelled
pyruvate (13C1-pyruvate) is the most commonly used substrate in hyperpolarised MRS and imaging (MRI) studies, being the end product of
glycolysis and undergoing a number of anabolic and catabolic transformations in energy metabolism. For cancer studies, two important metabolic
pathways for pyruvate are the formation of lactate via lactate dehydrogenase, or acetyl-CoA prior to entry into the tricarboxylic acid (TCA) cycle.
Pyruvate to lactate exchange in tumours has been studied as a potential marker for the efficacy of anticancer drugs in preclinical studies.3 More
recently, the use of hyperpolarised pyruvate in MRI has been investigated in several clinical studies of prostate, brain and breast cancers.4–6
Hyperpolarised 13C-labelled urea (13C-urea), which is not metabolised in tissue, except in gut flora, has also been used as a perfusion marker in
tumours.7
For use in routine clinical work, semiquantitative parameters describing pyruvate to lactate exchange, such as the lactate-to-pyruvate signal
ratio, are being evaluated for diagnostic and therapeutic applications.6 Clinical applications require these parameters to be straightforward and
rapidly obtained without the need for expert mathematical input. However, there is also a need for robust quantitation of kpl*, the fractional rate
constant for pyruvate signal conversion to lactate, and other related parameters from the 13C spectroscopic data, in order to validate simplified
biomarkers8 and contribute to an understanding of the complex biochemistry of the tumour microenvironment, in which lactate plays a crucial
role in energy production, metastasis and immune suppression.9,10 Preclinical animal systems can make a significant contribution to this field.
Bankson et al.11 found that a simple parameter describing the normalised lactate signal as a fraction of the sum of pyruvate and lactate signals
was significantly biased by pyruvate delivery. Such information is important to aid interpretation of similar parameters accessible in clinical
studies.
Mathematical models are required to extract kinetic parameters from dDNP data. Previously, we developed a general model of pyruvate to
lactate exchange, incorporating an arterial input function (AIF) acquired from measurements in sampled arterial blood, to investigate pyruvate
delivery in addition to its metabolism.12 For the current study, the general model was further developed to provide not only estimates of kpl and
the clearance of pyruvate signal from blood into the tissue, Kip, but also the losses of pyruvate and lactate signals from the tissue arising from both
physical signal erosion and biological processes. Kip is of particular relevance, due to the influence of pyruvate delivery on semiquantitative
measures of pyruvate metabolism11 and where blood flow effects of treatments are important to understand. Estimates of klo, the specific
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fractional rate constant for the loss of lactate signal from tumour tissue into the blood circulation, is relevant to understanding the high concentra-
tion of lactate observed in systemic blood of tumour-bearing subjects.13,14 An analogous general model was developed to describe the fate of
urea in tumour tissue. Previously, we also introduced the precursor-product model for hyperpolarisation studies, which uses the measured tumour
pyruvate signal as input for the lactate signal, in order to calculate kpl.
12 A similar ‘arterial input-less’ model was also developed by Khegai et al.15
and adopted by Larson et al.16 For the current study, the precursor-product model was further developed to account for an observed delay
between the appearance of the lactate and pyruvate signals in tumour tissue following administration of hyperpolarised pyruvate and to enable
estimation of total lactate losses from tumour tissue.
The main aim of the current study was to use the general models to carry out a comprehensive analysis of the fate of exogenously adminis-
tered hyperpolarised pyruvate and urea in a rat tumour model. Thus, delivery parameters for pyruvate and urea, defined as the clearance rates of
hyperpolarised pyruvate and urea signals from arterial blood into tumour tissue (Kip and Kiu, respectively), the forward and reverse fractional rate
constants for pyruvate-lactate signal exchange (kpl and klp, respectively) and the fractional loss rate constants for hyperpolarised pyruvate, lactate
and urea signals due to efflux from tumour into blood (kpo, klo and kuo, respectively) were estimated. The influence of arterial blood pressure, as a
principal determinant of tumour blood flow in experimental tumours,17–19 on Kip and Kiu, was investigated. We hypothesised that hyperpolarised
pyruvate provides the same information on the permeability of the tumour vasculature as hyperpolarised urea, due to efficient carrier systems in
each case. The results confirmed that the use of urea in hyperpolarisation experiments did not provide any information on the tumour microcircu-
lation over and above what could be obtained from pyruvate alone. A second aim was to interrogate the modified precursor-product model to
investigate the kinetics of the delayed lactate signal in tumour tissue and the total lactate signal losses from tumour tissue arising from
metabolism, efflux into blood and signal loss, in addition to estimating kpl. Incorporation of a tumour ‘waiting room’ compartment into the model,
in which pyruvate was unavailable for metabolism (described by kavail), enabled more accurate estimates of kpl, with kavail likely reflecting the
degree of functional tumour vascularisation. Estimating total lactate losses from tumour tissue at different scanning repetition times (TRs) enabled
calculation of the average flip angle (θ) and lower limits on the longitudinal relaxation times for pyruvate and urea (T1p and T1u, respectively) in
tumour tissue.
2 | METHODS
2.1 | Animal preparation
Animal experiments were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986, with local ethical approval
and following published guidelines for the use of animals in cancer research.20 In-house bred adult male BDIX rats (originally supplied by Charles
River UK Ltd, Margate, UK) were used for these experiments. Breeding was carried out under barrier conditions, but the health status of the
animals used was not specifically tested. Using an aseptic technique under general anaesthesia, rats were subcutaneously implanted in the rear
dorsum with fragments of the rat P22 sarcoma,12 a tumour originating in our laboratory and used here at early passage generations.19 After
several weeks, when tumours reached a mean diameter of approximately 15 mm, the animals were transferred to a dedicated animal scanner
facility and prepared for MRS, as described previously.12 Briefly, animals were anaesthetised with isoflurane (5% induction; 1.5%–2% maintenance
in 1:1 O2:N2O at 2 L/min). Rectal temperature was monitored and maintained at 37
C throughout surgical procedures using a homoeothermic
blanket (Harvard Apparatus, UK) and an overhead lamp. Two blood vessels were cannulated: a femoral vein for delivery of the hyperpolarised
materials and a femoral artery for blood pressure monitoring and AIF, T1 and θ estimations (see below). Cannulas were primed for surgery with
heparinised saline and rats were heparinised postsurgery with 0.1 ml of 1000 units per ml heparin by intravenous bolus injection via the
cannulated femoral vein.
2.2 | Preparatory MR methods
Following surgery, the animals were transferred to a dedicated animal holder for scanning, where the arterial cannula was connected to a chamber
for arterial blood collection and the venous cannula was connected to an automated injection system (Figure 1A,B). The arterial blood-collecting
chamber was connected to a custom-made pump for arterial blood withdrawal, operated as previously described.12 The chamber itself was of
similar design to that previously described,12 with the addition of a fibre optic temperature probe (PalmSense AMS Technologies AG, Martinstried,
Germany) glued inside the chamber to measure the temperature of the withdrawn blood (Figure 1B). The cannula dead-space to the chamber was
100 μL and the total chamber volume was 275 μL.
The holder was then positioned at the centre of a Bruker 7-T, 300-mm bore animal magnet system, initially consisting of an Avance II scanner
with a 400-mT/m, 120-mm diameter gradient insert, and subsequently an Avance III scanner with a 660-mT/m, 120-mm gradient insert. Identical
MR sequence acquisition parameters and the same RF coil were used on both systems to minimise any intersystem differences. Anaesthesia was
maintained using isoflurane and medical air at 2 L/min via a nose cone, and the body temperature continued to be maintained in the scanner using
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a thermostatically controlled heating blanket and warmed air. A 20-mm13C/1H tuned surface coil for transmission and receiving signal
(Bruker Biospin MRI GmbH, Ettlingen, Germany) was supported 1–2 mm above the tumour (to avoid artefacts due to animal movement during
respiration). A 6.7 M sodium 13C1-acetate phantom was placed in the same location on the surface coil for all experiments to provide a reference
signal and the arterial blood-collecting chamber was positioned next to the phantom, as shown in Figure 1A,C. Structural images were
acquired using a fast low-angle shot (FLASH) sequence with field of view (FOV) = 6  6 cm, matrix size 512  512, θ = 30, TR = 114 ms, echo
time (TE) = 6 ms and NEX = 1. Tumour structural images were used to estimate tumour volumes selected for MRS.
2.3 | Hyperpolarisation experiments with 13C1-pyruvate and
13C-urea
For the hyperpolarised MR experiments, two samples were prepared: (i) 13C1-pyruvic acid (PA) and (ii) 12 M
13C-urea dissolved in 3:2 12C-
DMSO:D2O, both containing 15 mM OXO63 trityl radical (Oxford Instruments, Abingdon, UK). Next, 1.5 mM DOTAREM (Guerbet, Roissy,
France) was added to each sample to enhance the final polarisation level; 45.5 ± 0.5 mg (35 μL) of the PA sample was flash-frozen in a sample
cup using liquid nitrogen, after which 35 μL of the urea sample was frozen on top. The dual frozen sample was inserted into a HyperSense
(Oxford Instruments) dDNP system and polarised for 2 hours. The polarisation of PA alone took less than 1 h. Following acquisition of a FLASH
image, as described above, the hyperpolarised frozen sample was dissolved with superheated 40 mM HEPES buffer solution and transferred
under pressure to the custom-designed automated injection system21 connected to the femoral vein cannula (Figure 1A), ready for rapid injection
into the rat. The receiving vessel also contained a predetermined aliquot of 2.0 M sodium hydroxide solution required to neutralise the PA acidity.
F IGURE 1 Experimental setup for arterial blood sampling and blood/tumour MRS; not to scale. (A) Approximate positions of subcutaneous
tumour on the rat, surface coil, phantom and blood chamber; the blue arrow shows the direction of administration for hyperpolarised pyruvate
and urea; the red arrow shows the direction of arterial blood flow. (B) Details of the blood chamber and connecting cannulas. (C) An example
FLASH image of a tumour, including the phantom and chamber and the approximate positions of the surface coil and slices 1 and 2, with the
green/blue shading indicating the tumour volume within slice 2
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The final concentrations of PA and urea were 150 and 121 mM, respectively (PA animal dose 0.75 mmol/kg). Following hyperpolarisation of PA
and urea, the dissolution transfer time from the polariser to the receiving vessel was 6 s, at which time the injection procedure was triggered
(t = 0), whereby 5 ml/kg of the solution containing hyperpolarised substrate was automatically injected through the femoral vein cannula, over a
period of 13 s; the automated injector provided a reproducible delivery profile.21 MRS data acquisition began at t = 0 for experiment 1 and
t = 40 s for experiments 2 and 3 (see below).
One-dimensional MRS 13C spectra were collected using a 0.5-ms Gaussian RF pulse, with 8-mm slice selection and a nominal θ of 20ο for a
slice incorporating the arterial blood-collecting chamber and the phantom (slice 1) and a slice-incorporating tumour tissue (slice 2) (Figure 1C).
Slice-localised free induction decay signals (256 points, 50 ppm sweep width) were acquired with a different TR depending on the experiment
performed, as described below. Approximately 10 min after injection, the femoral cannula was flushed through with 0.5 ml of heparinised saline.
The above procedure was carried out three sequential times in each animal, except that only PA was hyperpolarised and administered in the third
run (experiment 3). The individual experiments are summarised in Figure 2A and described in detail below.
In experiment 1, 1.0 ml of arterial blood was withdrawn at a rate of 1.0 ml/min, during which time the hyperpolarised signal was continuously
acquired using TR = 1 s, to provide data for simultaneously estimating the AIFs for pyruvate and urea.
In experiment 2, arterial blood was withdrawn at 1.0 ml/min to completely fill the chamber and then held stationary, with signal acquired from
t = 40 s, using TR = 4 s.
In experiment 3, arterial blood was withdrawn and signal acquired as in experiment 2, except using TR = 0.211 s for rapid signal erosion from
the applied RF pulses.
Experiments were carried out in the same order for each animal. Signal time-courses from the chamber in experiments 2 and 3 provided data
for estimating T1p and T1u in arterial blood and the average RF flip angle (θ) transmitted by the surface coil. For each of these injections, simulta-
neous signals were also acquired from slice 2 containing tumour tissue (Figure 1C).
Throughout the scanning procedures, arterial blood pressure and respiration rate were monitored continuously using an in-line pressure
transducer (CWE Inc., Ardmore, PA) and surface pressure transducer (SA Instruments Inc., Stony Brook, NY), respectively, in order to assess the
physiological state of the animals. Mean arterial blood pressure (MABP) measurements during experiment 1 were also used to determine their
influence on delivery of hyperpolarised pyruvate and urea to tumour tissue (Kip and Kiu, respectively). Approximately 3 min after each hyp-
erpolarised substrate injection and data acquisition, an arterial blood sample was taken to determine blood pO2, pCO2 and pH (ABL80/800 Flex
blood gas analyser, Radiometer Ltd, Crawley, UK). At the end of the procedures, animals were sacrificed via an intravenous overdose of sodium
pentobarbitone.
2.4 | Obtaining a signal time-course
Data were processed using custom Matlab software (MathWorks, Natick, MA) to provide magnitude spectra for chamber blood (slice 1) and
tumour tissue (slice 2). In a development from our previous study,12 MR spectral baselines were corrected by selecting baseline points on an aver-
aged spectrum from the time-course. From the defined baseline points, interpolated baseline corrections (Savitzky Golay filtered) were then cre-
ated and applied to each time-course spectrum. The resulting spectra were integrated (Matlab trapz function) to produce a signal time-course for
each spectral component (13C1-pyruvate,
13C1-lactate,
13C-urea). Any remaining small nonzero offsets in the signal time-courses were accounted
for by fitting for an offset term (not explicitly shown in the equations below), in initial analyses of each dataset. The fitted offsets were then car-
ried through as fixed values, so that the same offset was used in obtaining parameter estimates from different mathematical models applied to an
individual dataset. Due to complexities in quantitation of 13C spectra and uncertainties, for instance in polarisation level and B1 homogeneity, the
kinetic parameters described below should be considered apparent rate constants.15
2.5 | Flip angle and T1 estimates from arterial blood
T1p and T1u were estimated in blood for subsequent application in tumour modelling, as reported by others.
22,23 Use of blood minimises the
effects of metabolism, which are difficult to eliminate in solid tissues. Our online method means that T1 was determined with minimal delay and
degradation of the blood sample and holding the blood stationary eliminated signal losses from blood flow. The equation used to estimate T1
relaxation effects depends on both T1 and the applied flip angle (θ):





where M (t, n) is the decaying magnetisation as a function of TR and the nth pulse/data acquisition, and Mo is the initial magnetisation. The non-
uniform B1 profile of the surface coil results in a reduced θ (from the original set value of 20) as a function of distance. Equation 1 was solved
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simultaneously for T1p, T1u and θ using data from experiment 2 (TR = 4 s) and experiment 3 (TR = 0.211 s) (see Appendix A). It was assumed that
T1 for lactate (T1l) = T1p and that θ derived from pyruvate data could also be applied to urea data.
2.6 | Obtaining an AIF
The experimentally measured signal time-course from arterial blood passing through the chamber differs from the actual AIF experienced by the
tumour because of delay and dispersion of the signal between the chamber and the tumour, and relaxation losses due to T1 and RF pulses in the
F IGURE 2 Summaries of (A) The three experiments carried out sequentially in each rat and (B-D) The different models used for parameter
estimation. TR is the scan repetition time; AIF is the arterial input function as ‘seen’ by tumour tissue; T1p and T1u are the estimated longitudinal
relaxation times for hyperpolarised pyruvate and urea, respectively, in blood; θ is the estimated average flip angle; Rp and Rl are estimated lumped
fractional rate constants comprising tumour losses from T1s, θ and efflux into blood (kpo and klo) for pyruvate and lactate, respectively, as defined
in Equations 4 and 5 in the main text; Ru is the equivalent parameter for urea (Equation 7); tumour kpl and klp are the forward and reverse
fractional rate constants for pyruvate-lactate signal exchange, respectively; kavail is the fractional rate constant for transfer of pyruvate signal from
the nonexchanging to the exchangeable tumour compartment in the ‘waiting room’ model in (C); kloss(lactate) is the fractional rate constant for total
loss of lactate signal from tumour = Rl + klp; Kip and Kiu are the clearance rates from arterial blood into tumour tissue for pyruvate and urea,
respectively; CP and CU are the respective AIFs. Kil and CL are the equivalent parameters for lactate, shown in blue to denote that they were not
included in the model equations because no lactate signal was detected in arterial blood
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chamber. The deconvolution of these effects from the measured signal time-course in the chamber blood has been described previously,12 assum-
ing that blood in the chamber is well mixed and a gamma-variate function describes the AIF, with an exponential term describing dispersion in the
measuring chamber. Fits of signal time-courses from experiment 1 using this method were compared with those obtained from a ‘spectral’ fitting
method,24 in which a sum of exponential basis functions is convolved with a square wave input (representing the infusion schedule) to derive the
AIF. This method has the advantage of making minimal assumptions about the shape of the AIF or its arrival time (see Appendix B). The AIFs
obtained from the spectral fitting method were then used in all the estimations of the tumour parameters derived from the general models
summarised in Figure 2.
2.7 | Estimation of kinetic parameters in tumours: general models
Following intravenous injection of PA, 13C1-lactate and occasionally
13C1-alanine are observed in tumours. The focus of the present work was on
the kinetic exchange between 13C1-pyruvate and
13C1-lactate. The general models used to describe the fate of pyruvate and urea in tumour tissue
are illustrated as compartments in Figure 2B-D. Pyruvate metabolism is described as a two-way exchange model for metabolic conversion
between 13C1-pyruvate and
13C1-lactate (Figure 2B). In the absence of any measurable signal from hyperpolarised lactate in arterial blood, this is





PP tð ÞþklpLP tð ÞþKipCP tð Þ ð2Þ
dLP
dt
¼ kplPP tð Þ Rlþklp
 
LP tð Þ, ð3Þ
where PP(t) and LP(t) are the pyruvate and lactate signals (arbitrary units per ml tumour tissue), respectively, deriving from the pyruvate AIF, CP tð Þ
(arbitrary units per ml arterial blood). All tumour signals were normalised to tumour volume in slice 2, calculated from the FLASH images (signal
per ml tumour), enabling estimation of Kip in millilitres of blood cleared per min per millilitre tumour tissue (ml.min
1.ml1). Because the volumes
of the different tumour compartments (Figure 2) are unknown, all other parameter estimates are fractional rate constants and independent of
tumour volume. kpl (s
1) and klp (s
1) are, respectively, the fractional forward and reverse rate constants for pyruvate-lactate signal exchange in
tumour tissue. Rp and Rl are lumped parameters incorporating the other main losses of pyruvate and lactate signals, respectively, from tumour

















1) and klo (s
1) are the fractional loss rate constants for pyruvate and lactate signals due to efflux from tumour into blood, respec-
tively, and T1s/θ were derived from arterial blood. Detailed solutions of Equations 2 and 3 are given in Kazan et al.
12
The general model used to describe the fate of urea in tumour tissue (Figure 2C) is similarly described by the following equations:
dUU
dt






1cos θð Þ½ 
TR
þkuo, ð7Þ
where UU(t) is the urea signal in the tumour deriving from the direct urea input function Cu(t); Kiu has the units ml.min
1.ml1, as described
above for the equivalent pyruvate parameter; Ru is the lumped loss parameter; and kuo is the fractional loss rate constant for urea signal due to
REYNOLDS ET AL. 7 of 20
efflux from tumour into blood. Because urea is not metabolised in tumour tissue, there are no losses equivalent to kpl and klp. The solution to
Equation 6 is given by:
UU tð Þ¼CU tð Þ
O
Kiu exp Ru tð Þ: ð8Þ
All analyses were carried out in Matlab (version R2016b). The tumour tissue signal time-courses were fitted to the general models shown in
Figure 2B,C using a nonlinear optimiser (Nelder Mead25) that incorporated fixed values for the signal arrival times, in order to obtain the least
squares fit and extract the required parameter estimates (Figure 2). The signal arrival times were estimated from prior fits to the initial part of
the pyruvate and lactate signal time-courses. Using the general model for pyruvate-lactate conversion, as described above, the following
tumour parameters were estimated using the AIF and the tumour signal time-courses in experiment 1: Kip, kpl, klp, Rp, Rl; where (Rp + kpl) and
(Rl + klp) represent the fractional rate constants for total loss of pyruvate and lactate signals from tumour tissue, kloss(pyruvate) and kloss(lactate),
respectively:




1cos θð Þ½ 
TR
þkpoþkpl ð9Þ




1cos θð Þ½ 
TR
þkloþklp: ð10Þ
Corresponding parameter estimates obtained for urea were Kiu and Ru.
2.8 | Estimation of kinetic parameters in tumours: precursor-product models
Previously12 and in the current study, we detected no lactate signal in the blood chamber during PA infusion, such that there was no observ-
able arterial delivery of hyperpolarised lactate to the tumour (Kil = 0). Under these conditions, hyperpolarised pyruvate in the tumour is the
only source of hyperpolarised lactate in the tumour. Therefore, a precursor-product model, in which the tumour pyruvate signal was used as
the input for lactate, was used to provide estimates of kpl and kloss(lactate) from experiments 1, 2 and 3 (Figure 2 and Appendix C). In a devel-
opment from our previous study,12 the raw pyruvate signal per ml tumour time-course was used as the input for the lactate data. The
nonlinear optimiser (Nelder Mead25) was used to obtain the least squares solution and extract estimates of kpl and kloss(lactate). Estimates of
kloss(lactate) from experiments 1 and 2 were used to solve for tumour tissue θ, using Equation 10 and assuming that T1l, klo and klp remained
constant between experiments. A lower limit estimate of T1l in tumour tissue was then estimated by substituting these tumour estimates of
θ and estimates of Rl into Equation 5, with klo set to 0. Similarly, using Equation 7, a lower limit estimate of T1u in tumour tissue was
calculated (with kuo set to 0).
Delays of a few seconds were routinely observed between the arrival times of the tumour pyruvate and lactate signals. In the standard
precursor-product model and the general model, the time delays were estimated then incorporated into the fits as fixed values. In the final model
used, the precursor-product model was modified to include an extra compartment to account for the delayed arrival time of the lactate signal. This
extra ‘waiting room’ compartment was described by a fractional rate constant denoted as kavail (s
1), estimated in addition to kpl and kloss(lactate)
(Figure 2D). The least squares solution was again obtained using the Nelder Mead optimisation algorithm. Further details of the precursor-product
models and delays are provided in Appendix C.
All the mathematical models used and the tumour parameters estimated are summarised in Figure 2A. The source code for the various models
are available upon request.
2.9 | Statistics
Statistical analysis of the kinetic parameter estimates obtained from different modelling procedures was carried out using GraphPad Prism
software version 7.0b for Mac OS X (GraphPad Software Inc., San Diego, CA). Two-way paired Student's t-tests were used for statistical
comparison of two parameter sets estimated in the same group of animals and a one-way ANOVA with repeated measures, followed by a Tukey
post-hoc test, was used for comparison of more than two parameter sets. Datasets were not tested for normal distribution. Linear regression
analysis was used for comparing different parameters in individual animals. Values are expressed as mean ± SEM. In all cases, differences between
results were described as significant if the probability corresponding to the relevant statistic was less than 0.05.
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3 | RESULTS
3.1 | Animals and tumours
A group size of 12 tumour-bearing animals was chosen on the basis of previous estimates of kpl, where the SEM was approximately 6% for nine
animals.12 Some attrition was anticipated due to experimental complexity, but no specific exclusion criteria were set. In practice, one animal was
sacrificed prior to experiment 2 due to unacceptable injectate pH, one was sacrificed prior to experiment 2 following blood loss from the cannula-
tion site and, in a third, there was very poor signal-to-noise ratio in the tumour for both experiments 1 and 3, which precluded analysis. Results
from these three animals were excluded from the final analyses. The tumour geometrical mean diameter from in vivo caliper measurements in
three dimensions for the animals included in the final analyses was 14.7 ± 1.2 mm; the animals weighed 318 ± 13 g (n = 9).
3.2 | Estimates of T1p, T1u and θ in arterial blood
Figure 3 shows an example of the spectra acquired in arterial blood (red) and tumour tissue (blue) for an individual animal. Figure 4A illustrates the
signal decays, with associated fits, in the blood chamber for experiments 2 and 3. Figure 4B shows the associated estimates of θ, T1p and T1u from
arterial blood for the group as a whole. Mean θ for the slice was estimated as 9.7 ± 0.9 degrees. T1p and T1u were significantly different from each
other (16.6 ± 1.2 and 10.4 ± 1.2 s, respectively; p < 0.0001). Figure 4C shows that there was no significant effect of blood temperature on esti-
mates of T1s over the observed temperature range in the chamber (p = 0.920 and p = 0.466 for the slopes of the fitted lines being nonzero, for
pyruvate and urea, respectively). Marjanska et al.23 estimated the T1 of pyruvate as 31 ± 1 s in ex vivo rat blood at 9.4 T at room temperature but
as 13.2 ± 4.3 s in the carotid artery scanned in vivo, a value much closer to ours. Notably, in our previous study,12 we used an estimated T1p in
F IGURE 3 Time-course plot of slice-selected 13C spectra obtained from the arterial chamber (red) and tumour tissue (blue) in an individual
animal from experiment 1. Acquisition was started (time = 0) after a trigger signal, provided by the HyperSense at the point of dissolution. Every
third spectrum in the time-course is shown for clarity. Projected at the rear of the time-course are the mean spectra (rescaled for visibility) for the
respective slices showing the detected metabolites. Spectra are referenced to acetate at 177 ppm; the frequency shift in signal between chamber
and tumour is due to inhomogeneity in the field
REYNOLDS ET AL. 9 of 20
arterial blood of 43 ± 1 s for use in tumour modelling. However, the previous study estimated combinations of T1p and θ from a single experiment,
rather than using simultaneous equations from different TR periods to provide a discrete estimate of Tlp, as done here. The individual arterial
blood T1p, T1u and θ estimates for each animal were applied in the analysis of the respective animal's tumour tissue, with no temperature
correction made.
3.3 | AIFs and the general models
Figure 5 illustrates the processes for obtaining and using pyruvate and urea AIFs. Visually, the spectral method provided a closer fit to the arterial
blood data in the chamber than the gamma-variate (Figure 5A). This was confirmed for the animal group as a whole, where the spectral method
yielded residual sum of squares for the fits to the arterial blood data that were 32% ± 7% and 7% ± 3% lower than the gamma-variate fits, for
pyruvate and urea, respectively (n = 9 animals). Figure 5B shows the derived AIFs as ‘seen’ by the tumour following correction for dispersion
effects, and also the actual blood signal data points per ml chamber arterial blood. In Figure 5C, fits to the tumour data using the general models
(Figure 2B,C) that incorporate AIFs derived from the gamma-variate and spectral methods are shown (red and blue lines, respectively) (refer to
the figure legend for further details). Because the spectral analysis method provided the best fits to the blood data, the tumour pyruvate and urea
fits derived from the spectral method AIFs were used for the subsequent steps in the general model analysis.
3.4 | Estimates of kpl, klp and losses using the general models
kpl was estimated as 0.049 ± 0.006 s
1 (n = 9) using the general model (Figure 6A), which is very similar to that obtained previously for the P22
tumour under similar conditions.12,26 As expected, estimates of klp from the general model were very low compared with kpl and overall were
indistinguishable from zero (0.003 ± 0.003 s1; Figure 6B).
F IGURE 4 Analysis of arterial blood in experiments 2 and 3. (A) Examples of signal time-courses in arbitrary units (a.u.) for pyruvate and urea
in arterial blood for experiment 2 (TR = 4 s) and experiment 3 (TR = 0.211 s) in the same individual animal, as shown in Figure 3. Signal
acquisition was started 40 s into the infusion time of hyperpolarised compounds to ensure that the blood chamber was filled with arterial blood
from the femoral cannula. Data points are shown as blue crosses; magenta lines are fits through the data (as described in Appendix A).
(B) Parameter estimates for T1s for pyruvate and urea and average flip angle; each point represents an individual tumour and bars are means ±
SEM for n = 9; p value is from a two-tailed paired t-test. (C) Variation in T1s with blood temperature; lines are fitted by linear regression analysis
and the slopes of the lines are insignificantly different from 0, with p = 0.920 and p = 0.466 for pyruvate and urea, respectively; n = 9
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The general model for pyruvate-lactate exchange also provided estimates of the parameter Rl, as defined in Equation 5, such that klo could be
calculated. Accurate estimates of klo would help to describe the fate of lactate in tumour tissue following metabolic perturbation. Figure 6C,D
shows the Rl and klo estimates (0.053 ± 0.008 and -0.025 ± 0.01 s
1, respectively). The most obvious feature of the data is that the klo estimates
are all negative, with the exception of a single outlier attributable to a particularly high estimate of Rl, as seen in Figure 6C. Negative klo suggests
an influx of lactate from blood into tissue. However, if there are discrepancies between T1l and θ in blood versus tumour tissue, these could easily
account for the negative values obtained.
The same loss parameters for urea (Ru and kuo, Equation 7) were compared with those for pyruvate (Rp and kpo, Equation (4), as shown in
Figure 6E,F. A higher blood T1 for pyruvate than for urea (Figure 4) is consistent with Ru being higher than Rp in tissue (Figure 6E; p = 0.047). The
fractional rate constants kpo and kuo were negative (Figure 6F), as described for lactate (Figure 6D). Assuming that this is due to blood values for
T1s and θ being inaccurate estimates of the corresponding tumour values, any further calculations based on these values are quantitatively
meaningless.
3.5 | Estimates of the clearances of pyruvate and urea from blood to tumour tissue using the general model
The blood clearance parameters, Kip and Kiu, are dependent on blood flow rate and the permeability of the tissue vasculature to the particular
solute, described mathematically by Ki = E x F, where E is the fraction of solute extracted or cleared from the blood on a single pass and F is the
blood flow rate in ml blood per min per ml tissue.27 Therefore, any difference in Ki between pyruvate and urea would denote a difference in
permeability of the tumour vasculature to the two solutes, because they were administered simultaneously, ensuring identical blood supply
conditions.
Figure 7A shows that there was a highly significant correlation between Kip and Kiu in individual animals. Furthermore, Kip and Kiu were
equivalent (0.149 ± 0.028 and 0.148 ± 0.029 ml.min1.ml1, respectively; p = 0.975), suggesting that the P22 tumour vasculature is equally
permeable to pyruvate and urea.
F IGURE 5 Estimation and use of arterial input functions (AIFs) using the general model, in the same individual animal as shown in Figures 3
and 4. (A) Signal time-courses for pyruvate and urea in the arterial blood in the chamber, as blood was withdrawn via the femoral artery in
experiment 1 (black crosses); red lines are assuming a gamma-variate shape for the AIF; blue lines are fits from spectral analysis (Appendix B).
(B) AIFs for pyruvate and urea (CP and CU) derived from the gamma-variate (red) and spectral (blue) fitting procedures and correcting for delay
and dispersion in the circulation and signal decay, as described in the main text; black crosses are the raw data with baseline correction.
(C) Measured tumour signal time-courses for pyruvate and urea (black crosses) and the fitted data based on the gamma-variate AIF (red line) and
spectral AIF (blue line)
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3.6 | Influence of physiological status on Kip and Kiu estimated from the general model
General anaesthesia is a well-known cardiovascular and respiratory depressant and, as such, is likely to influence the estimated values of Ki.
Figure 7B shows MABP and the respiration rate measured shortly after arterial cannula implant (experiment 0 in Figure 7B) to the end of the
experimental procedures. Both parameters were depressed from normal unanaesthetised values, as expected, and tended to reduce with time,
although stabilising towards the end of the procedure. MABP was 72 ± 4 mmHg at the start of the experiment (Figure 7B), which was somewhat
lower than we have previously measured in the same animal strain, with propofol26 or Hypnorm/Hypnovel anaesthesia,28 as opposed to the
isoflurane anaesthesia used here. Consistent with a depressed respiration rate, average arterial oxygen partial pressure (pO2), calculated over the
whole experimental time-course, measured 64 ± 3 mmHg, down from the normal range of 80–100 mmHg. The arterial partial pressure of CO2
and arterial pH (42 ± 0.8 mmHg and 7.4 ± 0.03, respectively) were within the normal ranges.
Because blood flow to experimental tumours is highly sensitive to changes in arterial blood pressure,17–19 the relationships between Kip and
Kiu and MABP were investigated to determine whether variable MABP between animals could explain the interanimal variability in Kip and Kiu.
The results are shown in Figure 7C. The correlation was marginal, with statistical significance reached for urea (p = 0.025), but not for pyruvate
(p = 0.11). There was no significant correlation between Kis and tumour size (as estimated from caliper measurements), which was the expected
result for the tumour size range used29 (data not shown).
3.7 | Estimates of kpl and kloss(lactate) in tumour tissue using the precursor-product models
Figure 8A shows an example of tumour signal time-courses for pyruvate and lactate from experiment 1 (TR = 1 s). The raw pyruvate signal (black
crosses in Figure 8A) was used as the input for the lactate signal. Using the original precursor-product model without a waiting room compart-
ment, kpl was estimated as 0.049 ± 0.006 s
1, which is exactly the same as for the general model, providing a useful cross-check.
When a waiting room compartment was added to the model to account for the delay in arrival of the tumour lactate signal, it follows that the
estimate of kpl would increase, although the increase did not reach statistical significance in this case (0.069 ± 0.014 vs. 0.049 ± 0.006 s
1;
F IGURE 6 Analysis of tumour metabolism and losses using the general model. (A) Estimates of kpl, the fractional rate constant representing
pyruvate-lactate metabolism; (B) Estimates of klp, the fractional rate constant representing reverse metabolism lactate-pyruvate; (C) Estimates of
Rl, the fractional rate constant representing the main losses of lactate from tumour tissue, comprising losses from T1l, θ and klo, as defined in
Equation 5 in the main text; (D) Estimates of tumour klo calculated from Equation 5 in the main text, which uses estimates of T1s and θ from
arterial blood in the chamber, as described in the main text; (E) Estimates of Ru and Rp, the fractional rate constants representing the main losses
of urea and pyruvate from tumour tissue, comprising losses from T1u/T1p, θ and kuo/kpo, as defined in Equations 7 and 4, respectively, in the main
text; (F) Estimates of tumour kuo and kpo calculated from these equations, which use estimates of T1s and θ from arterial blood in the chamber. In
(A-F), data points represent individual tumours; bars represent mean ± SEM; n = 9; * represents a significant difference between groups;
p#x02009;= 0.047 and p = 0.285 for (E) and (F), respectively (two-tailed paired t-test)
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p = 0.064). The fractional rate constant kavail describes the turnover of the waiting room compartment (see Appendix C). Figure 8B shows that
kavail was highly variable between animals and, for kavail more than approximately 1.0 s
1 (i.e., complete turnover of the compartment in 1 s or
less), estimates of kpl were independent of whether the original or waiting room precursor-product model was used. Furthermore, there was an
inverse relationship between kpl estimated from the waiting room model and kavail. This suggests that a constant absolute rate of pyruvate-lactate
exchange could be maintained by a faster turnover of the available labelled pyruvate pool, when pyruvate is retained in the ‘waiting room’ for a
considerable time. As expected, the additional waiting room compartment made no difference to the estimate of kloss(lactate) (0.048 ± 0.003
vs. 0.049 ± 0.003 s1 in each case; p = 0.609).
Figure 8C shows the effect of shortening TR on estimates of kloss(lactate) in tumour tissue. There was no statistically significant difference
in the values across all three TRs (p = 0.481; ANOVA with repeated measures), but there was a statistically significant difference between the
data at TR = 1 and 4 s (p = 0.044; Tukey's multiple comparison post-test). The calculated tumour θ was 7.2 ± 0.7 degrees, which compares
with 9.7 ± 0.9 degrees estimated from the arterial blood data (Figure 4). The lower limit estimate of T1l in tumour tissue was 24.3 ± 2.2 s,
which compares with 16.6 ± 1.2 s for T1p estimated from the arterial blood data (Figure 4). Similarly, the lower limit estimate of T1u in tumour
tissue was 14.0 ± 1.3 compared with 10.4 ± 1.2 s for arterial blood (Figure 4). The effects of arterial blood versus tumour tissue θ and T1 esti-
mates on tumour parameter estimates derived from the general model are illustrated in Table 1. The data show that varying T1 and θ had a
small but significant effect on Kis, but no significant effect on the other parameters, with kpl shown to be particularly robust, as predicted from
the model equations.
4 | DISCUSSION
The upregulation of the glycolytic pathway in tumours is being actively investigated as a target for therapy.30 In this study, we have refined and
extended the experimental and analytical methods previously published12 for studying pyruvate metabolism in tumour tissue using dDNP and
F IGURE 7 Analysis of pyruvate and urea delivery to tumours. (A) Correlation between the clearance rates of urea (Kiu) and pyruvate (Kip)
from blood to tumour tissue; the blue line is the line of best fit by linear regression; the black line is the line of equivalence; each point represents
an individual tumour; n = 9. (B) Variation in mean arterial blood pressure (MABP) and respiration rate of animals throughout the time-course of
experiments 1 to 3; data at 0 on the horizontal axis are taken immediately after completion of the cannulation procedure, as described in the main
text; each point represents mean ± SEM; n = 9. (C) Correlation between Kip and Kiu and MABP for experiment 1; the solid lines are the lines of
best fit by linear regression; black symbols are pyruvate; blue symbols are urea; each point represents an individual animal; n = 9
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compared parameter estimates for its tumour uptake and efflux with that of urea, a nonmetabolised marker. Our findings help to clarify the fate
of pyruvate in tumour tissue and the utility of urea as a perfusion marker for dDNP experiments.
4.1 | General model: delivery
A general model incorporating an AIF provides a full picture of pyruvate fate in tumour tissue, from delivery to efflux. Although a gamma-variate
function gave a good fit for defining AIFs as used previously,12 a spectral fitting method, introduced here, proved superior and was used for the
F IGURE 8 Analysis of tumour data using the precursor-product models. (A) An example of tumour pyruvate and lactate signal time-courses in
arbitrary units (a.u.) from experiment 1 (TR = 1 s), in the same individual animal as shown in Figures 3 to 5; data points are shown as crosses; the
line through the lactate data is derived from the convolution of the pyruvate and lactate time-courses, using the raw pyruvate date as input for
the lactate; (B) kpl versus kavail, where kavail is the fractional rate constant for transfer of pyruvate signal from the nonexchanging to exchanging
tumour compartment in the ‘waiting room’ model (Figure 2D). kpl is estimated with a waiting room compartment (solid red symbols) or without
(open black symbols); each tumour is represented by a red and an open symbol; n = 9; (C) Variation of kloss(lactate) with variation in TR, using the
raw pyruvate data as input for lactate; symbols are mean ± SEM for n = 9; model 2b in Figure 2 was used for the deconvolutions; * represents a
significant difference between groups, p = 0.044 (Tukey's multiple comparisons test)
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main results. A similar model for 13C-urea enabled a direct comparison to be made of the fate of pyruvate and urea in tumour tissue, the latter
having been used previously as a blood perfusion marker in dDNP experiments.7,31,32
In mammals, urea is an end product of amino acid metabolism, with further catabolism performed by bacteria in the gut.33 It is a small but
highly polar molecule with low lipid solubility. Nevertheless, it is often described as freely diffusible through lipid bilayers, its transport being
facilitated by molecular transporters. UT-B urea transporters are found in many nonrenal cells and all endothelial cells studied so far, including
capillary endothelial cells.34,35 Although some authors have assumed that intravenously administered urea remains in the vasculature of tumours,
at least for the short observation period available for dDNP,32 others have shown it readily entering the interstitium.36 In a dDNP study, the
apparent diffusion coefficient for 13C-urea was estimated to be very similar to that of water, also implying rapid clearance of urea from the blood
to the interstitium.37 Our study has confirmed that urea is rapidly cleared from blood into tumour tissue and, furthermore, that the rate of urea
clearance (Kiu) is equivalent to that of pyruvate (Kip).
Because Ki = E x F and pyruvate and urea were administered simultaneously, our results indicate that permeability of the tumour vasculature
to the two solutes, and not only their Kis, were equivalent. The absolute estimates of Kis were variable between animals, indicating intertumour
variability in vascular function. The estimates were also somewhat lower than the expected blood flow rate of the P22 tumour, previously esti-
mated to be around 0.4 ml of blood per min per g of tumour, for MABP 80–90 mmHg.19,38,39 A reduced driving pressure for tumour blood flow,
arising from the relatively low arterial blood pressures measured here, could explain the low Kis obtained. Indeed, a statistically significant direct
correlation between Kiu and MABP was found, although a tendency for Kip to correlate with MABP did not reach statistical significance. A larger
subject group would be needed to determine this relationship for sure. All the Ki values were less than the expected 0.4 ml.min
1.ml1 for F, even
at the higher end of the MABP range, suggesting that the uptakes of both pyruvate and urea into tumour tissue are somewhat permeability
limited (E < 1.0), making neither an ideal blood flow marker. This would require direct investigation but, in any case, the equivalence of Kis for
pyruvate and urea suggests that the inclusion of urea in dDNP experiments has no real benefit for providing information on blood flow over and
above what can be obtained from pyruvate alone.
Notably, our estimates of Kiu were roughly an order of magnitude lower than those for the similar parameter, Ktrans for urea, previously publi-
shed by Chen et al.7 in transgenic prostate tumours. Together with a blood flow rate of 0.6 ml.min1.ml1 for this tumour type,40 this would yield
a value for E well above 1.0, which is impossible, indicating that the estimate of Ktrans was unrealistically high. Inaccuracies in parameter estimates
are a major problem in MRS/MRI,41 with efforts being made to overcome such obstacles in order to progress full translation of hyperpolarisation
techniques to the clinic.8 It is worth noting that the term ‘perfusion’ has been used by different investigators to refer to different phenomena in
tumours. Bahrami et al.32 used perfusion to refer to the total amount of pyruvate or urea in tissue, and so as not to be confused with blood flow
rate, F, or the blood clearance term Ki is used here.
4.2 | General model: metabolism and losses
Assuming that the reactions catalysed by lactate dehydrogenase (LDH) are at or close to chemical equilibrium, the 13C-dDNP experiments are
primarily measuring label exchange between pyruvate and lactate, rather than net production of lactate.42 Thus, the negligible estimate of klp is
TABLE 1 Comparison of T1 and θ estimates derived from arterial blood and tumour tissue and their effects on tumour tissue parameter
estimates using the general model
T1s and θ derived from arterial blood T1s and θ derived from tumour tissue
p value (paired t-test)mean SEM mean SEM
T 1p/l (s) 16.6 1.2 24.31
a 2.2 0.015*
T1u (s) 10.4 1.2 14.01
a 1.3 0.06
θ (degrees) 9.7 0.9 7.2 0.7 0.046*
Kip (ml.min
–1.ml–1) 0.149 0.028 0.194 0.042 0.021*
kpl (s
–1) 0.049 0.006 0.05 0.006 0.699
klp (s
–1) 0.003 0.003 0.005 0.005 0.221
Rp (s
–1) 0.057 0.008 0.047 0.013 0.194
Rl (s
–1) 0.053 0.008 0.056 0.009 0.215
Kiu (ml.min
–1.ml–1) 0.148 0.029 0.206 0.04 0.003*
Ru (s
–1) 0.083 0.017 0.119 0.06 0.436
alower limits on the estimates.
*statistically significant difference at the 5% level.
data are for n = 9 subjects.
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consistent with the LDH reaction lying heavily towards lactate and a relatively large lactate pool in the P22 tumour.26 The estimate of kpl obtained
here was very similar to those obtained previously in the P22 tumour.12,26
We detected no 13C-labelled lactate signal in arterial blood as reported previously in rats12 and by others in mice,14 although a small signal
was observed by Marjanska et al., using a coil directly surrounding the carotid artery in rats.23 Blood lactate concentration is normally in the low
mM range but higher in tumour-bearing mice14 and in some cancer patients.13 Serrao et al.14 found evidence for export of 13C-labelled lactate
from the intracellular to the extracellular space of tumours in dDNP experiments in vivo, consistent with tumour-promoting effects of lactate
occurring between different cell populations within the tumour microenvironment.9,10 They also found a significant concentration of 13C-labelled
lactate (2.4 μmol/g) in mixed venous and arterial blood 30 s after intravenous administration of 13C-labelled pyruvate, as measured from
perchloric acid extracts, approximately 50% of which could be attributed to lactate release from tissues other than blood. Taken together, these
results point to a marked efflux of lactate from tumour tissue into venous blood, which is generally not detectable by 13C1-pyruvate-based dDNP
experiments. Indeed, recent evidence suggests that lactate produced by tumours is exchanged extremely rapidly with the circulation and that
circulating lactate is a primary substrate for the TCA cycle in most tissues and tumours.43,44 Unfortunately, our estimates of the fractional rate
constant for lactate efflux from tumour into blood (klo) and the equivalent parameters for pyruvate and urea (kpo and kuo) were negative. Accurate
estimates of efflux parameters would enable calculation of tumour distribution volumes for these solutes. Others have calculated the distribution
volumes, denoted VT, of hyperpolarised urea and butanol, in transgenic prostate tumours in mice.
40 Especially notable was the surprisingly low VT
for butanol (0.25 ± 0.19), which is lipid soluble and readily diffusible in tissue, with the VT for urea even lower (0.10 ± 0.07). However, as for our
results, these estimates were found to be highly dependent on the assumed values for T1 and so are likely to be inaccurate.
4.3 | Precursor-product model
The precursor-product model provides a relatively straightforward approach to estimating kpl in tumours via dDNP and is the most practical
approach, if this is the only parameter of interest and there is no detectable lactate input from blood. In addition, repeat experiments in which TR
was varied enabled estimates of θ and a lower limit on T1l for tumour tissue to be obtained, which clearly showed that estimates of these parame-
ters in arterial blood were poor surrogates for the tumour tissue. Although T1 is mainly governed by interactions between the
13C-nucleus and
protons, it is well known that T1 can be modified by other environmental factors. Oxygenation differences between arterial blood and tumour tis-
sue could partially account for the observed differences in T1 estimates. Although we did not detect signal from lactate in blood, we cannot
exclude the possibility that pyruvate metabolism in fresh arterial blood also shortened the blood T1p via a combination of oxidative metabolism in
leucocytes and low level production of lactate in leucocytes and/or erythrocytes. Recent advances in mapping T1s for hyperpolarised probes in liv-
ing tissue have been made using balanced steady state free precession acquisitions,45 but estimates are still compromised to some extent by
blood flow and are difficult to apply to rapidly metabolised probes with short T1 products or closely spaced frequencies. In future experiments,
use of a volume transmitting coil, in combination with a surface receiving coil, would reduce uncertainty issues with θ and aid T1 estimations. In
addition, a single experiment incorporating both short and long TRs to estimate T1s and θ, as used by Puckeridge et al.,
46 would reduce scanning
time, and the use of a B1-insensitive adiabatic pulse, such as BIR, would improve B1 homogeneity and flip angle consistency for use with a surface
coil. In any event, although kpl is a very robust parameter, and the clearance parameters Kip and Kiu estimated from the general model were only
moderately T1-dependent (Table 1), much more accurate estimates of tumour T1 are required before solute effluxes can be investigated reliably.
In addition, it should be noted that calculation of the efflux fractional rate constants kpo, klo and kuo are also dependent on estimates of the lumped
loss parameters Rp, Rl and Ru, respectively (Equations (4, 5 and 7), and so we cannot discount the possibility that underestimation of these parame-
ters (from the general model analysis) could also have contributed to the negative efflux parameter values obtained.
The accuracy of kpl estimates was improved by addition of a ‘waiting room’ compartment to the precursor-product model. Bankson et al.,
11
using Akaike's criterion, found that inclusion of two spatial compartments (intravascular and extravascular/extracellular), in addition to two chemi-
cal compartments (pyruvate and lactate), in their modelling, provided a good balance between accuracy of parameter estimation and complexity
compared with having a single spatial compartment in which pyruvate is immediately available for chemical exchange. Furthermore, extending the
model to include three spatial compartments (intravascular, extracellular and intracellular), although a more accurate description of the biology,
provided no further statistical advantage under the conditions of their experiments. Our waiting room model is also made up of two spatial com-
partments in the tumour, although the biological significance of the waiting room is unclear. It most likely reflects the complexities of the tumour
microcirculation, in which blood flow rate is highly heterogeneous,38 and filling of the whole vascular bed with contrast agent entering through
supplying arterioles can take several seconds.47 The fractional rate constant, kavail, describing the kinetics of pyruvate transfer from the waiting
room compartment to the exchangeable pyruvate compartment, was highly variable between animals, suggesting that there was considerable
intertumour, in addition to intratumour, heterogeneity in vascular function, which is consistent with the estimates of Kip obtained from the general
model. kpl estimates from the waiting room model were inversely related to kavail, suggesting that the absolute rate of pyruvate-lactate exchange
could be maintained over the whole kavail range. However, without knowing the concentrations of pyruvate in each compartment, this cannot be
known for certain. In future studies, it would be worth determining whether kavail is a useful descriptor of tumour vascular function. Others have
suggested that pyruvate flux into cells through monocarboxylate transporter 1 (MCT-1)48 and/or its efflux from cells via MCT-449 could also
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influence appearance of the lactate signal. Our model cannot discriminate between these different processes, but the waiting room model does
provide a more reliable estimate of kpl based on a better description of the biological processes involved in pyruvate-lactate exchange than simpler
models with only one spatial compartment.
5 | CONCLUSION
The precursor-product model is straightforwardly applied to tumour 13C1-pyruvic acid dDNP data and so has obvious clinical utility, primarily for
estimating kpl. This model is improved by the incorporation of a nonexchanging spatial compartment to account for the delay in appearance of the
lactate signal compared with the pyruvate signal in tumour tissue. We have demonstrated some of the further information that can be gained
from modelling the full process in preclinical tumour models, from pyruvate delivery to its metabolism and efflux back into the blood. The model-
ling revealed that the P22 tumour vasculature is as permeable to urea as pyruvate, suggesting that use of urea provides no additional information
on the tumour microcirculation over and above what can be obtained from pyruvate alone. The study also highlights the need for rigorous
processes controlling signal quantitation and accurate estimation of signal decay in tumour tissue, if absolute estimations of biological parameters
are required.
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ENDNOTE
* Note that throughout the text k represents a fractional rate constant in s–1, whereas K represents a rate in defined units, as described in the main text.
Subscripts i and o refer to movement of pyruvate/lactate/urea in and out of tumour tissue, respectively; subscripts p, l and u refer to pyruvate, lactate
and urea, respectively.
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APPENDIX A: Simultaneous fits to blood data
To measure the flip angle, θ, in blood, a dataset with a rapid RF excitation pulse train (TR=0.211 s; experiment 3; pyruvate only) was used to
erode the magnetization, so that the term e
n:TR
T1 in Equation 1 tended towards 1. This data was then least squares fitted to M t,nð Þ¼M0 cosθð Þ
n to
obtain an initial estimate of the flip angle (θÞ in blood. The next step was to fit pyruvate data obtained from blood with a longer TR=4 s
(experiment 2), using the initial estimate of the θ already calculated, using Equation 1, to provide an initial estimate of T1p in blood. Following this,
the urea time series with the same TR=4 s was fit to Equation 1, using the estimate of θ already obtained from the pyruvate data, to calculate an
initial estimate of T1u. Finally, the time-courses for signal from blood for both pyruvate and urea were least squares fit simultaneously, solving for
θ, T1p and T1u using the values already calculated above as initial estimates of these parameters.
APPENDIX B: Spectral analysis method for deriving the AIF
The spectral analysis method, previously used in positron emission tomography tracer studies,24 was used to derive the tumour AIFs for pyruvate
and urea.
The AIF is described as the convolution of a square wave (to describe the shape of the venous infusion schedule of hyperpolarised pyruvate/
urea), with a positive sum of kinetic exponential basis functions (to provide an unconstrained fit of the data) and is given by:





The measured signal time-course in the chamber (AIFmeas) is a convolution of AIF with a single exponential for dispersion, accounting for the
mixing of the blood in the chamber:
AIFmeas tð Þ¼AIF tð Þ
O
K1exp ktð Þ, ðA2:2Þ
where
N
denotes the convolution operator; S(t) is the square wave; N is the total number of basis functions included in the fitting process
(N = 100); K1 is the flow rate of arterial blood into the chamber in ml s1; k is the fractional loss of signal from the chamber due to relaxation
losses (T1 and θ) and the turnover of blood in the chamber (K1 divided by the chamber volume).
Thus, the problem becomes one of determining the values of α that best fit the measured data given a set of N predefined β values. The
β values cover a full spectrum of feasible kinetics ranging from β = 0.0001 s1 to the fastest measurable dynamic, β = 1 s1 (subject to the
constraint α > 0). The positivity constraint for α resolves the problem of finding a solution to an underdetermined set of equations and imposes a
sparse solution on the spectral part of the fitting process and is solved using a non-negative least squares algorithm.24,50
This whole process corresponds to fitting Equation A2.2 to the measured blood chamber data and enables estimation of AIF(t), which is
equivalent to CP and CU for pyruvate and urea, respectively, in Figure 2.
APPENDIX C: Precursor-product models
Estimates of kpl (forward fractional rate constant for pyruvate-lactate exchange) and kloss(lactate) (fractional rate constant for total tumour lactate
loss) can be obtained without the need for a blood arterial input function using the precursor-product relationship between tumour pyruvate and
tumour lactate signal time-courses (PP(t) and LP(t), respectively). Precursor-product models were based on the full general models shown in
Figure 2B,D.
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A delay of a few seconds was consistently observed between PP(t) and LP(t), suggesting that not all the tumour pyruvate was immediately
accessible to the enzyme catalysing its exchange with lactate. As described previously,12 this can be modelled as a simple delay, which is then
used as a fixed value in the subsequent modelling. The delay length, d, was determined by iteratively fitting the signal over a range of values for d
from 0 to 10 s and selecting the value with the smallest residual sum of squares. kpl and kloss(lactate) were derived from the differential Equation 3
in the main text:
dLP
dt




LP tð Þ¼PP tð Þ
O





where kloss(lactate) = Rl + klp and Equation A3.1 describes the precursor-product model based on Figure 2B. The final lactate concentration was
calculated by accounting for the delay in the lactate signal by time shifting it by a duration of d and using the associated decay constant, dc = exp
(d*[kT1 + kθ]), to correct for the loss of signal in this time, where kT1 = 1/T1 and kθ = (1 – cosθ)/TR. In experiment 3, due to the very short TR,
the signal time-courses were only measured after the peak in tissue signal occurred and so it was necessary to include a starting value for the
tissue lactate fit.
However, the observed delay between tumour lactate and pyruvate signals most likely reflects turnover of pyruvate in an additional ‘waiting
room’ tumour tissue compartment, as shown in Figure 2D and described by:
dLP
dt





¼ kavailPP tð Þ RPþkavailþkT1þkθð ÞPE tð Þ,
where PE(t) is the concentration of pyruvate in the exchangeable compartment. Solution of these equations yields:
LP tð Þ ¼PP tð Þ
O








where kavail is the fractional rate constant for pyruvate turnover in the waiting room compartment.
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